ATOS - Atossa Analyst Forecast Prices

Atossa Therapeutics (ATOS) specializes in developing innovative treatments for breast tumors. The stock price trend on GURU.Markets, which currently stands at 17.04, demonstrates scaling potential driven by patents and low mass-production costs. Furthermore, the business relies on a flawless raw material distribution system, which completely eliminates disruptions in drug supply chains.

ATOS Atossa Therapeutics, Inc. Price Target Chart (07/04/2022 - 11/11/2026)

Analytical breakdowns for Atossa (ATOS)

- stock value and consensus price forecast:

Stock Price atossatherapeutics.com|ATOS - Consensus Target

- market capitalization statistics:

Market Value Atossa|ATOS - Total Company Value

- book capitalization information:

Net Asset Value per Share Atossa Therapeutics|ATOS - Company Book Value|Market Capitalization to Book Value atossatherapeutics.com|ATOS - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

ATOS - Company Net Income|Expected Net Income Atossa Therapeutics|ATOS - Price to Earnings Ratio|Future Price to Earnings Multiple Atossa Therapeutics Inc|ATOS - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Atossa|ATOS - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Atossa Therapeutics|ATOS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months atossatherapeutics.com|ATOS - Earnings growth in current year|Expected net earnings per share growth next year Atossa Therapeutics

Fundamental company analysis:atossatherapeutics.com (ATOS)

This indicator reflects the arithmetic mean of target prices from industry experts, serving as a benchmark for the business's fundamental value and market expectations for asset returns. The stable shift in the average target price is supported by the implementation of ESG standards and the bioethical transparency of Atossa Therapeutics (ATOS), which mitigates regulatory risks and ensures the company's sustainable capitalization within the biotechnology sector.

Competing companies